Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party AGIHO of the German Society for Hematology and Medical Oncology DGHOReportar como inadecuado




Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party AGIHO of the German Society for Hematology and Medical Oncology DGHO - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Annals of Hematology

, Volume 94, Issue 9, pp 1441–1450

First Online: 21 July 2015Received: 24 April 2015Accepted: 06 July 2015DOI: 10.1007-s00277-015-2447-3

Cite this article as: Sandherr, M., Hentrich, M., von Lilienfeld-Toal, M. et al. Ann Hematol 2015 94: 1441. doi:10.1007-s00277-015-2447-3

Abstract

Reactivation of viral infections is common in patients with solid tumour or haematological malignancy. Incidence and severity depend on the extent of cellular immunosuppression. Antiviral prophylaxis may be effective to prevent viral reactivation. In 2006, the Infectious Diseases Working Party of German Society for Hematology and Medical Oncology DGHO published guidelines for antiviral prophylaxis in these patient populations. Here, we present an update of these guidelines for patients with solid and haematological malignancies undergoing antineoplastic treatment but not allogeneic stem cell transplantation. Relevant literature for reactivation of different viruses herpes simplex virus HSV, varicella zoster virus VZV, hepatitis B virus HBV and respiratory viruses is discussed to provide evidence-based recommendations for clinicians taking care of this patient population. We recommend a risk-adapted approach with valacyclovir against HSV and VZV in patients treated with alemtuzumab, bortezomib or purine analogues. Seasonal vaccination against influenza is recommended for all patients with solid or haematological malignancies regardless of antineoplastic therapy. Hepatitis B screening is recommended in lymphoproliferative disorders, acute leukaemia, and breast cancer, and during treatment with monoclonal anti-B-cell antibodies, anthracyclines, steroids and in autologous stem cell transplantation. In those with a history of hepatitis B prophylactic lamivudine, entecavir or nucleotide analogues as adefovir are recommended to prevent reactivation.

KeywordsGuideline Antiviral prophylaxis Hepatitis B Cancer treatment  Download fulltext PDF



Autor: Michael Sandherr - Marcus Hentrich - Marie von Lilienfeld-Toal - Gero Massenkeil - Silke Neumann - Olaf Penack - Lena Bieh

Fuente: https://link.springer.com/







Documentos relacionados